Episode Details

TG Therapeutics just crashed 11%—despite posting a massive $240 million revenue blowout and raising its full-year guidance. Why the drop? Wall Street panicked when earnings missed targets after the company spent aggressively to scale manufacturing for a new subcutaneous version of its blockbuster MS drug, Briumvi. In this episode of Implied, we break down whether this selloff is just short-term noise over heavy spending… or a warning sign of lasting margin pressure. Tune in for the full breakdown behind the market's wild reaction!